Andere talen PsyBio Therapeutics Corp.

Aandelen

PSYB.H

CA6936971044

Vertraagde tijd Toronto S.E. Andere beurzen 05:24:13 29-03-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,01 ^CAD	-.--%		-.--%	-.--%

2021	PsyBio Therapeutics dient octrooi in op nieuwe psychedelische samenstellingen en behandelingsmethoden bij USPTO	MT
2021	PsyBio versterkt leiderschapsteam met benoeming van Dr. Michael Spigarelli als Chief Medical Officer	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

PsyBio Therapeutics : Reports Second Quarter 2021 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones	30-08-21
PsyBio Therapeutics : Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	16-08-21
PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs	16-08-21
PsyBio Therapeutics : Adds NMDA Receptor Antagonists and Associated Analogues into its Intellectual Property Portfolio	04-08-21
PsyBio Therapeutics : CEO and CMO to Participate in Fireside Chat at LifeSci Partners Summer Symposium	20-07-21
PsyBio Therapeutics : Announces Uplisting to OTCQB Venture Market	14-07-21
PsyBio Therapeutics : Files Novel Psychedelic Compositions and Methods of Treatment Patent With USPTO	13-07-21
PsyBio Therapeutics : Augments Intellectual Property Portfolio with Filing of Next Novel Psychedelic Compositions and Methods of Treatment Patent	13-07-21
PsyBio Therapeutics : Announces TSXV Approval of Share Buyback Program	28-06-21
Psybio Therapeutics Corp. Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds	22-06-21
PsyBio Therapeutics : Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie	22-06-21
PsyBio Therapeutics Corp. Announces Executive Changes	01-06-21
PsyBio Therapeutics Corp.'s Board intends to launch an Equity Buyback.	01-06-21
IRW-News: PsyBio Therapeutics Corp.: PsyBio Therapeutics beruft erfahrene pharmazeutische Führungskraft Bob Oliver in sein Board of Directors	21-04-21
PsyBio Therapeutics : Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors	21-04-21
PsyBio Therapeutics : Retains KCSA Strategic Communications for Investor Relations Services	09-04-21
PsyBio Therapeutics : Strengthens Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer	05-04-21
PsyBio Therapeutics : Strengthens its Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer	05-04-21
IRW-News: PsyBio Therapeutics Corp.: PsyBio Therapeutics beginnt mit Prozessentwicklung von eigenem biosynthetischem Norbaeocystin	23-03-21
PsyBio Therapeutics Announces Retention of Market Maker	04-03-21

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen PsyBio Therapeutics Corp.

Aandelen

PSYB.H

CA6936971044

Andere talen

Filters